NCT02799147View on ClinicalTrials.gov

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Leukemia, Acute LymphoblasticAcute Myeloid LeukemiaMixed-Lineage Acute Leukemias
Interventions
PROCEDURE

Allogeneic stem cell transplantation

DRUG

Fludarabine monophosphate

DRUG

Busulfan

DRUG

Bendamustine

Trial Locations (1)

197089

First Pavlov State Medical University of St. Petersburg, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER

NCT02799147 - GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | Biotech Hunter | Biotech Hunter